113



                                  EXHIBIT 32.2
                                  ------------



           This is an Exhibit to the Form 20-F of Sinovac Biotech Ltd.
           -----------------------------------------------------------


                     Attached find the following materials:


               Certification of Lily Wang pursuant to Section 906
               --------------------------------------------------
                        of the Sarbanes-Oxley Act of 2002
                        ---------------------------------








                                       114



                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection  with  the Annual  Report  on Form 20-F/A-3  for fiscal year ended
December 31, 2004 of Sinovac Biotech Ltd., a company organized under the laws of
Antigua and Barbuda (the  "Company"), as filed with the  Securities and Exchange
Commission  on the date  hereof  (the  "Annual  Report"),  I, Lily  Wang,  Chief
Financial Officer (Principal Accounting Officer of the Company certify, pursuant
to  18  U.S.C.   Section  1350  as  adopted  pursuant  to  Section  906  of  the
Sarbanes-Oxley Act of 2002, that:


1.   The Annual Report fully complies with the  requirements of Section 13(a) or
     15(d) of the Securities Exchange Act of 1934, as amended; and

2.   The  information  contained in the Annual  Report fairly  presents,  in all
     material respects, the financial condition and results of operations of the
     Company.



Dated: November 21, 2005                      /s/ Lily Wang
                                            ------------------------------------
                                            Lily Wang, Chief Financial
                                            Officer and Director (Principal
                                            Accounting Officer)















                               End of Exhibit 32.2

                                   ----------